HomeCompareCGIB vs MRK

CGIB vs MRK: Dividend Comparison 2026

CGIB yields 4.28% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $30.3K in total portfolio value
10 years
CGIB
CGIB
● Live price
4.28%
Share price
$25.24
Annual div
$1.08
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$562.71
Full CGIB calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CGIB vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCGIBMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CGIB + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CGIB pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CGIB
Annual income on $10K today (after 15% tax)
$363.55/yr
After 10yr DRIP, annual income (after tax)
$478.30/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $7,850.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CGIB + MRK for your $10,000?

CGIB: 50%MRK: 50%
100% MRK50/50100% CGIB
Portfolio after 10yr
$41.6K
Annual income
$5,180.42/yr
Blended yield
12.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CGIB
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CGIB buys
0
MRK buys
0
No recent congressional trades found for CGIB or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCGIBMRK
Forward yield4.28%2.76%
Annual dividend / share$1.08$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$26.4K$56.8K
Annual income after 10y$562.71$9,798.13
Total dividends collected$5.0K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CGIB vs MRK ($10,000, DRIP)

YearCGIB PortfolioCGIB Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,128$427.71$11,206$366.19$78.00MRK
2$12,351$444.81$12,650$502.35$299.00MRK
3$13,677$461.43$14,407$694.19$730.00MRK
4$15,112$477.54$16,585$967.82$1.5KMRK
5$16,663$493.12$19,342$1,363.89$2.7KMRK
6$18,338$508.16$22,913$1,947.19$4.6KMRK
7$20,144$522.64$27,662$2,823.89$7.5KMRK
8$22,091$536.56$34,159$4,173.35$12.1KMRK
9$24,187$549.92$43,337$6,308.80$19.1KMRK
10$26,443$562.71$56,776$9,798.13$30.3KMRK

CGIB vs MRK: Complete Analysis 2026

CGIBStock

To provide a high level of current income as is consistent with the preservation of capital.Distinguishing Characteristics Invests in a broad range of debt securities, including corporate bonds and debt securities issued by sovereign, quasisovereign and supranational entities. The fund may also invest in mortgage-backed securities issued by government-sponsored entities and federal agencies and instrumentalities that are not backed by the full faith and credit of the U.S. government and other asset-backed securities, including debt obligations that represent interests in pools of mortgages or other income bearing assets, such as consumer loans or receivables.Generally, the fund will invest at least 40% of its assets outside the United States.The fund may invest up to 15% of assets in bonds rated below investment grade (BB/Ba+ or below, or unrated, but determined by the fund’s investment adviser to be of equivalent quality) at the time of purchase, including high-yield corporate bonds or those issued by developing country governments and companies. Generally, the fund will maintain at least 90% of its assets in U.S. dollar currency exposure.

Full CGIB Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CGIB vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CGIB vs SCHDCGIB vs JEPICGIB vs OCGIB vs KOCGIB vs MAINCGIB vs JNJCGIB vs ABBVCGIB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.